Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …

CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …

Background T cell mediated hyperinflammatory responses such as cytokine release
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …

Chimeric antigen receptor (CAR) T-cell therapy is rapidly advancing, offering promising
treatments for patients with hematological malignancy. However, associated infectious …

Chimeric antigen receptor (CAR) T cell (CAR-T) therapy has emerged as a revolutionary
cancer treatment modality, particularly in children and young adults with B cell malignancies …

Simple Summary Targeted therapies in children with hematological malignancies moderate
the effects of cytotoxic therapy, thus improving survival rates. They have emerged over the …

Chimeric antigen receptor T-cell (CART) therapy constitutes a new treatment platform for
pediatric patients with relapsed/refractory malignancies. CARs are synthetic receptors …

Introduction Besides cytokine release syndromes (CRS) and immune effector cell-
associated neurotoxicity syndrome (ICANS), immune effector cell-associated HLH-like …

Introduction Chimeric antigen receptor (CAR) T-cell CD19 therapy is an effective treatment
for relapsed/refractory B-cell acute lymphoblastic leukemia. It can be associated with life …

Infection has emerged as the chief cause of non‐relapse mortality (NRM) post CD19‐
targeting chimeric antigen receptor T‐cell therapy (CAR‐T) therapy. Even though up to 50 …